ERBB2 and breast carcinoma: Clinical significance of intratumoral HER2 heterogeneity as a predictive factor for trastuzumab was reported in breast cancer; namely, homogeneously HER2 overexpressed breast cancer showed more benefit from trastuzumab-based treatment compared with heterogeneously HER2 overexpressed breast cancer [23].